ArticleBMC neurology2020
Risk of Parkinson's disease following gout: a population-based retrospective cohort study in Taiwan.
Article in BMC neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Association between gout, hyperuricemia, and Parkinson's disease: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.BMC neurology · 2022Pooled it
- Inflammatory rheumatic diseases and the risk of Parkinson's disease: A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- Association between gout, hyperuricaemia and Parkinson's disease risk: a cohort study in western Sweden (2001-2017).Rheumatology advances in practice · 2025Article
- Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective.Neuropsychopharmacology reports · 2024Review
- Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction.JMIR public health and surveillance · 2023Article
- Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean.Journal of rheumatic diseases · 2023Review
- Longitudinal follow-up study of the association with gout and Alzheimer's disease and Parkinson's disease in Korea.Scientific reports · 2023Article
- Dose-response meta-analysis on urate, gout, and the risk for Parkinson's disease.NPJ Parkinson's disease · 2022Review
- Serum Uric Acid Levels in Parkinson's Disease: A Cross-Sectional Electronic Medical Record Database Study from a Tertiary Referral Centre in Romania.Medicina (Kaunas, Lithuania) · 2022Article
- Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson's Disease: A Nationwide Cohort Study.Frontiers in pharmacology · 2022Article
- Identification of Drugs Associated with Lower Risk of Parkinson's Disease Using a Systematic Screening Approach in a Nationwide Nested Case-Control Study.Clinical epidemiology · 2022Article
- Hyperuricemia, Gout, and the Brain-an Update.Current rheumatology reports · 2021Review
- Clinical Association between Gout and Parkinson's Disease: A Nationwide Population-Based Cohort Study in Korea.Medicina (Kaunas, Lithuania) · 2021Article
- High Blood Uric Acid Is Associated With Reduced Risks of Mild Cognitive Impairment Among Older Adults in China: A 9-Year Prospective Cohort Study.Frontiers in aging neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe progressive neurodegenerative disorder Parkinson disease (PD) is well-established as the second most common neurodegenerative disease. Associations between the sequential risk of PD and gout have been addressed in other studies, but findings have been inconclusive. Accordingly, we executed the present study with the purpose of assessing PD risk in patients with gout.
methodsFrom Taiwan's National Health Insurance Research Database, we identified the data of patients newly diagnosed as having gout between January 1, 2000 and December 1, 2000. A cohort of patients without gout, matched for sex and age, was constructed for comparison. Hazard ratios (HRs) and the incidence rate of subsequent PD were calculated for both cohorts and separately for male and female groups. The gout and comparison cohorts consisted of 7900 patients each.
resultsThe HR for PD was not significantly higher in the gout cohort compared with the control cohort (HR 1.01, 95% confidence interval [CI], 0.93-1.31, P = .268), even after adjustment for age, urbanization, monthly income, sex, and comorbidities. We did not observe gender differences in the gout-PD association (male: HR 1.01, 95% CI, 0.88-1.36, P = .400; female: HR 1.11, 95% CI, 0.84-1.46, P = .466).
conclusionsOur study identified that there was no protective effect of gout for the risk of PD in the Taiwanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.